HuidaGene Therapeutics (辉大基因; HuidaGene), a global clinical-stage biotechnology company focused on developing genomic medicine, today announced the selection of Drs. Haiyan Jiang and Alvin Luk as the new members of the Scientific Advisory Board (SAB).
HuidaGene Appoints New Members to the Scientific Advisory Board Read More »
PhenomeX (Nasdaq: CELL), the functional cell biology company, today announced that Peter Silvester has been named to the PhenomeX board of directors, effective immediately.
PhenomeX Appoints Peter Silvester to PhenomeX Board of Directors Read More »
Babson Diagnostics today announced the addition of a clinical advisor who will bring valuable insights of the medical community in the ongoing development and introduction of the company’s new diagnostic blood testing service, BetterWay™. Andrew Carroll, M.D., a family physician and clinical assistant professor at the University of Arizona College of Medicine, will provide advice
Babson Diagnostics Welcomes New Clinical Advisor, Andrew Carroll, M.D. Read More »
AbbVie and Johnson & Johnson will withdraw the accelerated approvals for Imbruvica in mantle cell lymphoma and marginal zone lymphoma, the companies announced Thursday.
AbbVie, J&J Pull Two Accelerated Approvals for Imbruvica Read More »
JW Therapeutics announced that it has received the Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) of China for a clinical trial of relmacabtagene autoleucel injection (relma-cel) in patients with moderately or severely refractory systemic lupus erythematosus (SLE).
Regenative Labs announced that it will present two scientific studies demonstrating the efficacy of Wharton’s jelly allografts in complicated post-surgical wounds and late-stage sacral decubitus ulcers at the Symposium on Advanced Wound Care (SAWC) conference.
Astrocyte Pharmaceuticals Announces Theodore Liston, Ph.D., Vice President of Research, as Recipient of the 2022 Innovation and Progress Award from the Journal Stroke.
Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA ® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED).
Currently, there are no gene editing–based treatments on the market, but the technology continues its march toward potential FDA approval, with several products in mid- and late-stage trials.
Gene Editing Therapeutics Could Hit the Market in 2023 Read More »
Evecxia Therapeutics, Inc. today announced favorable safety, tolerability, pharmacokinetic, and pharmacodynamic data from a double-blind, placebo-controlled Phase 1, a two-part single ascending dose (SAD) and multiple ascending dose (MAD) trial of EVX-101 in healthy volunteers treated with escitalopram.
